Avalo Therapeutics vs Medicinova
Medicinova is the larger business, with $409,657 of revenue in fiscal 2025 against $59,000 for Avalo Therapeutics (6.9 times as much). Medicinova grew faster (-59.0% against -86.6%). Medicinova kept more of each dollar of sales as profit: a net margin of -2928.8% against -132642.4%. Avalo Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Avalo TherapeuticsAVTX, 2025 | MedicinovaMNOV, 2025 |
|---|---|---|
| Revenue | $59,000 | $409,657 |
| Revenue growth | -86.6% | -59.0% |
| Net income | −$78.3m | −$12.0m |
| Operating margin | -123601.7% | -3242.5% |
| Net margin | -132642.4% | -2928.8% |
| Return on equity | -72.4% | -23.1% |
| Free cash flow | −$51.5m | −$9.8m |
| Cash | $15.9m | $30.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 33 | — |
| Market value | $383m | $70.9m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 0 buys, 43 sales | 0 buys, 1 sales |